Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 Stuver, R., Michaud, L., Casulo, C., Advani, R. H., Budde, E. L., Barr, P. M., Batlevi, C., Caron, P. C., Constine, L. S., Dandapani, S., Drullinsky, P., Friedberg, J. W., Grieve, C., Hamilton, A., Hamlin, P. A., Hoppe, R., Horwitz, S. M., Khan, N., Matasar, M. J., Noy, A., Palomba, M., Schoder, H., Straus, D. J., Vemuri, S., Yahalom, J., Yang, J. C., Younes, A., Zelenetz, A. D., Moskowitz, C. H., Kumar, A., Moskowitz, A. J. AMER SOC HEMATOLOGY. 2022: 1756-1758

View details for DOI 10.1182/blood-2022-156382

View details for Web of Science ID 000893223201316